The Centers for Medicare & Medicaid Services will host a webinar Feb. 11 at 2 p.m. ET on updated hospital price transparency ...
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...
The Centers for Medicare & Medicaid Services yesterday announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations. Negotiations will occur this year and any ...
The selected medications treat a range of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus ...
The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...
The PBM measures included in the bill have been championed by Earl L. “Buddy” Carter, a Republican from Georgia and pharmacist, who has long tried to pass legislation to address business practices of ...
Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...
Negotiated prices for Kisqali and Verzenio, which the agency said cost Medicare over $1 billion in a year, would become effective starting 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results